Glaxosmithkline (GSK) has announced positive overall survival results from a study of its treatment for patients with 'mutation-positive metastatic melanoma'.The COMBI-d study showed a "statistically significant reduction in the risk of death" for the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) compared to dabrafenib monotherapy.Completion of this study was a post-marketing requirement for the Food and Drug Association's accelerated approval for the combination in the US.The final data from COMBI-d will be submitted to regulatory authorities for review in the coming months, GSK said.Patrick Vallance, the president of phamaeuticals research and development at GSK, said that the results "further reinforce the scientific rationale for combining MEK and BRAF inhibitors and underscore the potential of the combination of dabrafenib and trametinib in the treatment of BRAF V600 mutation-positive metastatic melanoma"."We are deeply grateful for the support and commitment of the patients, their families and the investigators who took part in this trial," he said.